NLRP3 and myeloid sarcoma: Obvious limitations, on the other hand, involve the retrospective character, recruitment bias (as an outpatient clinic specialized in MS), and the lack of patients with clear disease-causing mutations in the NLRP3- and TNFRSF1A gene for comparison.